OBJECTIVES: To assess the patterns of use of tests to monitor disease activity/progression among patients currently treated with disease modifying treatments (DMTs) for RRMS in EU. METHODS:  A multi-center retrospective chart-review study of MS patients was conducted in EU (UK/France/Germany/Italy/Spain) to collect de-identified data on diagnosis, clinical status, and disease management approaches. Healthcare providers (mostly neurologists) were screened for duration of practice (≥3yrs) and patient volume (≥15 MS patients/mo) and recruited from a large panel to be geographically representative in each country. Medical charts of next 10 consecutive MS patients were abstracted by each HCP. RRMS patients currently on DMTs were analyzed. RESULTS: CONCLUSIONS: Neurological exam and EDSS were used among most patients, while prevalence of use of other tests varied and increased with patient progression through treatment lines. At least one-fourth and one-fifth of patients across treatment lines had unknown T2 and gd-enhanced lesions respectively. Observed practice patterns may warrant further scrutiny to optimize care delivery and therapeutic interventions to alleviate disease burden.